Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review

about

Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review

Item

http://www.wikidata.org/entity/Q38971422

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Partial response to imatinib t ...... ort and mini literature review

@en

type

Item

label

Partial response to imatinib t ...... ort and mini literature review

@en

prefLabel

Partial response to imatinib t ...... ort and mini literature review

@en

P1476

Partial response to imatinib t ...... ort and mini literature review

@en

P2093

Dong Xia

http://www.w3.org/2001/XMLSchema#string

Liang Xu

http://www.w3.org/2001/XMLSchema#string

Libo Feng

http://www.w3.org/2001/XMLSchema#string

Qing Liu

http://www.w3.org/2001/XMLSchema#string

Xiaolong Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Gastrointestinal stromal tumors: molecular markers and genetic subtypes.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Gastrointestinal stromal tumours: origin and molecular oncology.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.

P304

2297-2301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2016.3614

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27698727

http://www.w3.org/2001/XMLSchema#string

P932

5038182

http://www.w3.org/2001/XMLSchema#string